Search

Selected EMA news

February 2025New medicines recommended for approval
Dyrupeg (pegfilgrastim) – biosimilar
Treatment to shorten the duration of neutropenia and help prevent febrile neutropenia after cytotoxic chemotherapy

Eltrombopag Accord (eltrombopag) – generic
Treatment of primary immune thrombocytopenia and thrombocytopenia associated with chronic hepatitis C
New information on…

Read more

Meeting program

Thursday, October 12*All times are in EET.

Read more

Uptake of CAR T cell therapy in Europe

Feb 05 2019 Posted in Advocacy news Tagged CAR T

Gene (editing) therapy continues to break ground in hematology, showing promising results in tackling severe blood cancers. Yet, its uptake in the European Union is slow, with few patients benefiting from it so far.

Read more

Restrictions

EHA is guided by the concept of supporting as many young investigators/clinicians as possible in their career development. Therefore, double awarding is not allowed.

Read more

100,000 Patient data sets: The value of data sharing to accelerate blood cancer research.

With almost 100,000 patient data sets identified and 63,000 already transferred to the HARMONY Big Data Platform, the HARMONY Alliance is fully equipped to facilitate state-of-the-art research into blood cancers.

Read more

The European Hematology Association (EHA) announces an Invitation to Tender (ITT) for PCO services for the EHA Annual Congress

The European Hematology Association (EHA) is pleased to inform the conference and meeting community that it will release an Invitation To Tender (ITT) for the appointment of a Professional Conference Organizer (PCO) for the EHA Congress in 2023.

Read more

IMI2 Call for Research Proposals

The indicative budget for this topic is 40 million Euro, half of which by way of an in kind contribution from Industry Consortium EFPIA (European Federation of Pharmaceutical Industries and Associations) companies.

Read more